The Role of Metoclopramide for Treatment of Functional Constipation in Children: A Double Blind Study
7.222
831
Abstract
Background: The treatment of functional constipation is a concern worldwide. Various studies have evaluated the effect of prokinetic agents such as cisapride in management of chronic constipation, however due to the possible lethal side effects, its consumption has been limited. In this study we assessed the effect of metoclopramide a drug with similar prokinetic effects and less side effects in management of chronic constipation.
Method: All pediatric patients less than 12 year of age with diagnosis of chronic functional constipation according to the ROME III criteria were included during the study period. Through this double blind study, patients were randomly divided into two groups. Group A received polyethylene glycol and placebo and group B polyethylene glycol with metoclopramide. The two groups were compared regarding their symptoms and Rome III criteria following therapy.
Results: Of the total 102 pediatric patients, 50 subjects completed regime A and 52 patients, regime B. The interval between defecations prior to treatment was 4.8±2.7 days in subjects of group A and 5.9±3.6 days in those of group B. Response to treatment; defined as decrease in signs and symptoms that would not fulfill Rome III criteria, and without any recurrence of fecal impaction with discontinuation of medication, was almost equal in both groups: 84% (42 of 50) in patients receiving regime A vs. 84.6% (44 of 52) in regime B group (p=0.39).
Conclusion: In this study we achieved no significant response from consumption of metoclopramide as a prokinetic agent in the treatment of chronic constipation of children.
Method: All pediatric patients less than 12 year of age with diagnosis of chronic functional constipation according to the ROME III criteria were included during the study period. Through this double blind study, patients were randomly divided into two groups. Group A received polyethylene glycol and placebo and group B polyethylene glycol with metoclopramide. The two groups were compared regarding their symptoms and Rome III criteria following therapy.
Results: Of the total 102 pediatric patients, 50 subjects completed regime A and 52 patients, regime B. The interval between defecations prior to treatment was 4.8±2.7 days in subjects of group A and 5.9±3.6 days in those of group B. Response to treatment; defined as decrease in signs and symptoms that would not fulfill Rome III criteria, and without any recurrence of fecal impaction with discontinuation of medication, was almost equal in both groups: 84% (42 of 50) in patients receiving regime A vs. 84.6% (44 of 52) in regime B group (p=0.39).
Conclusion: In this study we achieved no significant response from consumption of metoclopramide as a prokinetic agent in the treatment of chronic constipation of children.
Keywords
Constipation; Metoclopramide; Treatment
Zotero
Mendeley